The Cooper Companies, Inc. (NASDAQ:COO) Receives $110.25 Consensus Price Target from Brokerages

Shares of The Cooper Companies, Inc. (NASDAQ:COO - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $110.25.

Several research analysts recently weighed in on COO shares. Citigroup cut their target price on shares of Cooper Companies from $115.00 to $110.00 and set a "buy" rating for the company in a research note on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a "hold" rating in a research note on Thursday, March 13th. JPMorgan Chase & Co. cut their target price on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Piper Sandler restated an "overweight" rating and issued a $115.00 price target (down previously from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. Finally, Stifel Nicolaus lowered their price target on Cooper Companies from $115.00 to $105.00 and set a "buy" rating for the company in a report on Friday, March 7th.

Institutional Trading of Cooper Companies

A number of institutional investors have recently modified their holdings of COO. Price T Rowe Associates Inc. MD grew its holdings in shares of Cooper Companies by 517.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company's stock worth $324,466,000 after purchasing an additional 2,957,421 shares during the period. Norges Bank purchased a new stake in shares of Cooper Companies during the 4th quarter worth about $217,906,000. FMR LLC grew its holdings in shares of Cooper Companies by 97.6% during the 4th quarter. FMR LLC now owns 2,218,112 shares of the medical device company's stock worth $203,911,000 after purchasing an additional 1,095,805 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Cooper Companies during the 4th quarter worth about $64,826,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Cooper Companies by 17.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company's stock worth $399,340,000 after purchasing an additional 686,751 shares during the period. Hedge funds and other institutional investors own 24.39% of the company's stock.

Cooper Companies Price Performance

Shares of COO stock traded up $1.47 during mid-day trading on Wednesday, reaching $82.92. The stock had a trading volume of 1,519,674 shares, compared to its average volume of 1,467,845. Cooper Companies has a 12-month low of $69.81 and a 12-month high of $112.38. The company has a market cap of $16.58 billion, a P/E ratio of 42.52, a price-to-earnings-growth ratio of 2.25 and a beta of 1.08. The business has a 50-day simple moving average of $80.19 and a 200 day simple moving average of $90.20. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. On average, sell-side analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.